查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2008206

亞磷醯胺市場：按類型、形態、應用和最終用戶分類－2026-2032年全球市場預測

Phosphoramidite Market by Type, Form, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，亞磷醯胺市場價值將達到 13.8 億美元，到 2026 年將成長至 14.9 億美元，到 2032 年將達到 23 億美元，複合年成長率為 7.54%。

主要市場統計數據
基準年 2025 13.8億美元
預計年份：2026年 14.9億美元
預測年份 2032 23億美元
複合年成長率 (%) 7.54%

詳細的入門指南，說明了亞磷醯胺在實現精確寡核苷酸合成中的核心作用，該合成可用於治療、診斷和高級研究應用。

亞磷醯胺是一類基礎試劑，可用於固相寡核苷酸合成，其應用範圍廣泛，涵蓋治療性寡核苷酸到診斷探針等。隨著核酸技術的日益成熟，對精確合成的寡核苷酸（包括DNA和RNA序列以及胜肽核酸類似物）的需求也日益複雜，要求供應商提供高純度、優異穩定性以及特殊修飾的產品，以支持下一代治療方法。本文概述了亞磷醯胺的化學和操作特性，闡述了它們在常規實驗室工作流程和大規模臨床生產中不可或缺的作用，並將當前的行業趨勢置於更廣泛的科學和監管背景下進行分析。

技術創新、自動化和不斷提高的監管期望如何重塑亞磷醯胺供應商的投資重點、品質範式和商業化路徑。

在自動化、先進化學技術的整合以及治療和診斷流程日益成長的需求驅動下，亞磷醯胺領域正經歷多項變革。寡核苷酸合成的自動化提高了合成效率，同時也要求試劑能夠在高通量環境下提供可重複的性能。同時，特殊保護基團和骨架化學的應用拓展了合成寡核苷酸的功能，促使供應商透過開發修飾的亞磷醯胺和支持不同結合策略和穩定性特徵的特殊結構單元來豐富其產品組合。

2025 年美國新關稅對磷醯胺生態系統內的籌資策略、供應鏈本地化和長期供應商選擇的影響。

美國於2025年推出的關稅政策和貿易措施，促使整個寡核苷酸供應鏈的籌資策略進行重大調整。供應商和買家正透過近岸外包、策略性庫存調整以及供應商多元化等措施，來減輕關稅相關成本波動的影響。對許多企業而言，最直接的營運影響是加快審查合約條款和物流模式，以維持利潤率並確保研發和臨床生產計劃的按時完成。

精細的細分洞察，展示了應用需求、試劑類型、最終用戶要求和外形尺寸如何共同決定供應商的優先順序和價值提案。

細分市場分析揭示了不同應用領域、試劑類型、終端用戶和物理形態下的獨特需求特徵，這些特徵共同塑造了供應商的策略和產品開發重點。就應用而言，DNA寡核苷酸合成仍然是常規分子生物學和診斷領域的主要需求促進因素，而RNA寡核苷酸合成在以siRNA、反義寡核苷酸和mRNA相關技術為重點的治療項目中正變得日益重要。肽核酸合成是一個小眾但技術要求極高的領域，需要高度專業化的單體和配套的化學技術。每種應用對純度、保護基團和偶聯效率都有獨特的要求，這些要求指南原料的選擇和製程控制。

美洲、歐洲、中東和非洲以及亞太地區的製造能力、監管預期和需求狀況的差異如何重新定義籌資策略和風險管理。

區域趨勢反映了獨特的競爭和法規環境環境，這些因素影響籌資策略、合作夥伴選擇和風險管理方法。在美洲，對臨床階段治療計畫的集中需求以及成熟的診斷市場推動了對符合GMP標準的供應、快速技術支援和供應鏈透明度的期望。區域製造能力和完善的物流網路支援對時間要求嚴格的交貨，但也增加了買方對供應商的依賴風險。歐洲、中東和非洲（EMEA）地區的監管環境複雜多樣，包括西歐強大的研究生態系統和其他地區新興的臨床開發中心，這要求企業具備靈活的商業模式和對當地法規的專業知識。該地區也重視永續性和合規性報告，在供應商評估中，價格以外的因素也至關重要。

市場動態，以產品組合廣度、品質管治和策略製造夥伴關係關係為特徵，塑造了供應商差異化和買家決策。

在亞磷醯胺領域，主要企業與新興企業之間的競爭格局主要體現在產品組合的廣度、品質體係以及從研發到臨床生產的規模化支援能力。成熟的供應商憑藉其強大的分析能力和靈活的生產平台，能夠很好地滿足學術客戶（他們尋求廣泛的產品）和生物製藥開發公司（他們需要符合GMP標準的連續性生產）的需求。新參與企業和專業供應商則透過提供小眾的改性亞磷醯胺、快速的客製化合成服務以及全面的技術支援方案來脫穎而出，這些服務能夠幫助客戶加速序列設計迭代並縮短開發週期。

供應商和買家面臨的可操作的策略挑戰，旨在加強品質系統、實現生產多元化，並使經營模式與客戶的長期需求保持一致。

產業領導企業應優先考慮一系列合作舉措，以管控風險、把握機遇，並在磷醯胺領域實現商業性差異化。首先，投資於分析和法規遵循能力，以實現新化學品的快速合格，並為客戶提供清晰的文檔，以支援其臨床和診斷應用。其次，建構靈活的生產結構，平衡區域生產基地和儲備產能，以最佳化關鍵客戶的前置作業時間，同時降低貿易政策和物流中斷的影響。第三，根據治療趨勢，選擇性地擴展產品系列，開發改性磷醯胺和特殊磷醯胺，並將技術創新與可擴展的GMP製程結合。

我們高度透明的混合研究途徑，結合專家訪談、供應商審核和技術文獻整合，得出檢驗的見解和可操作的建議。

本研究採用混合方法進行綜合分析，結合了對技術相關人員的訪談、供應商審核以及對同行評審文獻、監管指南和行業技術期刊的二手資料分析。透過與合成化學家、採購經理和品質控制人員的深入訪談，我們開展了現場討論，以補充一手信息，從而揭示供應商績效的實際情況和認知，並重點關注生產限制和品管能負責人的考慮。此外，我們還對二手資料進行了嚴格評估，以提取與寡核苷酸試劑生產相關的、檢驗的技術趨勢、調查方法和監管先例。

策略性地整合各種趨勢，顯示將品質、生產規模和商業模式與不斷變化的治療和診斷需求相匹配，將決定未來的領導地位。

總之，儘管亞磷醯胺仍是不斷發展的寡核苷酸科學領域的核心技術，但供應商和採購格局正在發生顯著變化。自動化技術的進步和化學技術的改進提高了試劑品質和文件記錄的技術難度，而貿易政策和區域製造趨勢則要求採購和生產力計畫進行策略調整。學術界、合約研究、診斷和生物製藥等終端用戶現在要求供應商提供更全面的價值提案，將技術創新、供應可靠性和法規遵從性相應對力。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：亞磷醯胺市場：按類型分類

  • 改質亞磷醯胺
  • 單鹼式亞磷醯胺
  • 特殊亞磷醯胺
  • 通用亞磷醯胺

第9章：亞磷醯胺市場：依形態分類

  • 固體粉末
  • 解決方案

第10章：亞磷醯胺市場：依應用領域分類

  • DNA寡核苷酸合成
  • 肽核酸合成
  • RNA寡核苷酸合成

第11章：亞磷醯胺市場：依最終用戶分類

  • 學術研究機構
  • 合約研究機構
  • 診斷藥物生產商
  • 製藥和生物技術公司

第12章：亞磷醯胺市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：亞磷醯胺市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：亞磷醯胺市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國亞磷醯胺市場

第16章：中國亞磷醯胺市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AAT Bioquest, Inc.
  • Actylis
  • Amadis Chemical Company Limited
  • American International Chemical, LLC by LeBaronBrown Industries LLC
  • Beijing SBS Genetech Co., Ltd.
  • Bioneer Corporation
  • Biosynth Ltd.
  • BOCSCI Inc.
  • ChemGenes Corporation
  • Creative Biolabs, Inc.
  • Hongene Biotech Corporation
  • Integrated DNA Technologies, Inc. by Danaher Corporation
  • LGC Genomics Limited
  • Lumiprobe Corporation
  • Maravai LifeSciences Holdings, Inc.,
  • MedChemExpress
  • Merck KGaA
  • PolyOrg, Inc.
  • QIAGEN NV
  • Thermo Fisher Scientific Inc.
  • Tokyo Chemical Industry Co., Ltd.
  • Twist Bioscience Corporation
  • Wuhu Huaren Science and Technology Co., Ltd.
Product Code: MRR-EA74537D7BA2

The Phosphoramidite Market was valued at USD 1.38 billion in 2025 and is projected to grow to USD 1.49 billion in 2026, with a CAGR of 7.54%, reaching USD 2.30 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.38 billion
Estimated Year [2026] USD 1.49 billion
Forecast Year [2032] USD 2.30 billion
CAGR (%) 7.54%

A detailed primer on phosphoramidites explaining their central role in enabling precise oligonucleotide synthesis for therapeutics, diagnostics, and advanced research applications

Phosphoramidites are a foundational class of reagents that enable solid-phase oligonucleotide synthesis, underpinning a broad array of applications from therapeutic oligonucleotides to diagnostic probes. As the landscape of nucleic acid technologies matures, the demand profile for precision-synthesized oligonucleotides, including DNA and RNA sequences and peptide nucleic acid analogues, has become more nuanced, requiring suppliers to offer higher purity, enhanced stability, and specialized modifications that support next-generation modalities. This introduction outlines the chemical and operational characteristics that make phosphoramidites essential to both routine laboratory workflows and large-scale clinical manufacturing, while situating current industry dynamics within broader scientific and regulatory trends.

Transitioning from traditional synthesis paradigms to more sophisticated supply and manufacturing models, stakeholders must appreciate how reagent quality, lot-to-lot consistency, and supplier technical support directly affect downstream product performance. In practical terms, small differences in coupling efficiency, protecting group chemistry, or impurity profiles can cascade into significant impacts on synthesis yield, purification burden, and analytical characterization. The subsequent sections explore how technological innovation, policy shifts, supply chain pressures, and evolving end-user needs are reconfiguring the operational and commercial calculus for phosphoramidite producers and buyers alike.

How technical innovation, automation, and elevated regulatory expectations are reshaping supplier investment priorities, quality paradigms, and commercialization routes for phosphoramidites

The phosphoramidite landscape is experiencing several transformative shifts driven by integration of automation, advanced chemistries, and rising demand from therapeutic and diagnostic pipelines. Automation of oligonucleotide synthesis has accelerated throughput while demanding reagents formulated for reproducible performance in high-throughput environments. Concurrently, the adoption of specialized protecting groups and backbone chemistries has broadened the functional capabilities of synthetic oligonucleotides, incentivizing suppliers to expand portfolios into modified phosphoramidites and specialty building blocks that support diverse conjugation strategies and stability profiles.

Another major shift is the convergence of analytical rigor and regulatory expectations, which places a premium on comprehensive impurity profiling, traceability, and validated manufacturing processes. Analytical advancements such as ultra-high-resolution mass spectrometry and orthogonal chromatography methods are enabling tighter specifications and earlier detection of process-related impurities. In parallel, the commercialization of therapeutic oligonucleotides and the scaling of clinical manufacturing are prompting suppliers to reassess quality systems, supply continuity guarantees, and batch-release paradigms. Taken together, these dynamics are reshaping supplier investment priorities, partnership structures, and the value propositions presented to end users across academia, contract research, diagnostics, and biopharmaceutical development.

Impacts of new United States tariff measures in 2025 on procurement strategies, supply chain localization, and long-term supplier qualification decisions in the phosphoramidite ecosystem

Tariff policy and trade measures instituted by the United States in 2025 created a material reevaluation of procurement strategies across the oligonucleotide supply chain. Suppliers and buyers have responded with a mix of nearshoring, strategic inventory adjustments, and diversification of supplier bases to mitigate exposure to tariff-driven cost volatility. For many organizations, the immediate operational consequence was an accelerated review of contractual terms and logistics models to preserve margin and ensure on-time delivery for R&D and clinical production schedules.

Beyond short-term tactical responses, the tariff environment has catalyzed more structural shifts. Some manufacturers have explored establishing regional manufacturing nodes or toll-synthesis partnerships to localize production and reduce cross-border tariff burdens. Others have invested in supply chain transparency measures to support tariff classification challenges and dispute resolution. Additionally, procurement teams placed renewed emphasis on total landed cost assessments that integrate tariff risk, freight variability, and potential regulatory inspection delays. These actions together underline how trade policy has not only affected transactional pricing but also influenced longer-term decisions about supplier qualification, capacity planning, and strategic partnerships across the value chain.

Granular segmentation insights showing how application demands, reagent types, end-user requirements, and form factors jointly determine supplier priorities and value propositions

Segmentation insights reveal differentiated demand characteristics across application areas, reagent types, end users, and physical forms that collectively shape supplier strategies and product development priorities. In applications, DNA Oligonucleotide Synthesis remains a core demand driver for routine molecular biology and diagnostics, while RNA Oligonucleotide Synthesis is increasingly critical for therapeutic programs focused on siRNA, antisense oligonucleotides, and mRNA-adjacent technologies; Peptide Nucleic Acid Synthesis occupies a niche but technically demanding segment that requires highly specialized monomers and supporting chemistries. Each application imposes distinct purity, protecting-group, and coupling-efficiency requirements that inform raw material selection and process controls.

By type, the landscape differentiates between Single Base Phosphoramidite products that emphasize standardized performance and cost-effectiveness, Modified Phosphoramidite offerings that enable functionalized sequences and conjugation chemistries, Specialty Phosphoramidite variants tailored to proprietary or high-value applications, and Universal Phosphoramidite constructs designed to streamline certain synthesis schemes. These product categories present varying margins, regulatory pathways, and technical support needs for suppliers. Regarding end users, Academic Research Institutes prioritize breadth, affordability, and technical literature support; Contract Research Organizations demand scale, reproducibility, and rigorous documentation; Diagnostics Companies require rapid lot-to-lot consistency and regulatory traceability; Pharmaceutical Biotechnology Companies prioritize GMP-compliant supply and long-term contractual stability. Finally, on form factors, Solid Powder presentations are often preferred for ease of storage and shipping, while Solution-phase formats provide convenience for automated synthesis platforms and can reduce handling variability, influencing warehousing and cold-chain logistics considerations.

How divergent regional manufacturing capabilities, regulatory expectations, and demand profiles across the Americas, EMEA, and Asia-Pacific redefine sourcing strategies and risk management

Regional dynamics show distinct competitive and regulatory environments that influence sourcing strategies, partner selection, and risk management approaches. In the Americas, demand concentration around clinical-stage therapeutic programs and a deep diagnostics market create a high expectation for GMP-grade supply, rapid technical support, and supply chain transparency; regional manufacturing capabilities and advanced logistics networks support time-sensitive deliveries but also expose buyers to concentrated supplier risks. Europe, Middle East & Africa presents a diverse regulatory landscape with strong research ecosystems in Western Europe and emerging clinical development hubs elsewhere, driving a requirement for flexible commercial models and localized regulatory expertise. This region also emphasizes sustainability and compliance reporting, adding non-price dimensions to supplier evaluation.

Asia-Pacific is characterized by rapid capacity expansion, significant manufacturing scale, and a growing base of domestic developers moving into late-stage development, which together have implications for global supply balances and competitive pricing dynamics. However, variability in quality infrastructure and regulatory alignment across jurisdictions requires careful supplier qualification and stronger technical due diligence for companies procuring at scale. Taken together, regional considerations demand tailored engagement models from suppliers and bespoke risk mitigation strategies from buyers that reflect local regulatory pathways, logistics constraints, and end-user sophistication.

Market competitive dynamics underscored by portfolio depth, quality governance, and strategic manufacturing partnerships shaping supplier differentiation and buyer decisions

Competitive dynamics among leading and emerging firms in the phosphoramidite space center on portfolio breadth, quality systems, and the ability to support scale transitions from R&D to clinical manufacturing. Incumbent suppliers that combine strong analytical capabilities with flexible production platforms are positioned to meet the dual needs of academic customers seeking breadth and biopharma developers needing GMP-grade continuity. New entrants and specialty providers are differentiating through niche modified phosphoramidites, rapid custom synthesis services, and enhanced technical support packages that help customers accelerate sequence design iterations and shorten development timelines.

Strategic partnerships and contract manufacturing relationships have become increasingly important as buyers demand integrated supply solutions that include stability testing, custom packaging, and validated cold-chain logistics. Intellectual property around protecting-group chemistry and modification strategies also shapes competitive barriers, with companies investing selectively in proprietary building blocks that serve high-value therapeutic applications. Overall, the competitive landscape rewards suppliers that can demonstrate robust quality governance, transparent supply chain practices, and the operational agility to scale production while maintaining stringent impurity and traceability standards.

Actionable strategic imperatives for suppliers and buyers to strengthen quality systems, diversify production, and align commercial models with long-term customer requirements

Industry leaders should prioritize a set of coordinated actions to manage risk, capture opportunity, and drive commercial differentiation in phosphoramidites. First, invest in analytical and regulatory capabilities that enable faster qualification of new chemistries and provide customers with clear documentation to support clinical and diagnostic applications. Second, develop a flexible manufacturing footprint that balances regional production nodes with capacity reserves to mitigate trade policy and logistics disruptions while optimizing lead times for key customers. Third, expand product portfolios selectively into modified and specialty phosphoramidites that align with therapeutic trends, pairing technical innovation with scalable GMP pathways.

Additionally, cultivate deeper technical partnerships with end users to co-develop reagent specifications that reduce scale-up friction and enhance product performance. Strengthen supply chain visibility through serialization, enhanced traceability, and collaborative inventory planning with major customers. Finally, commercial teams should refine contractual models to reflect total landed cost and service-level commitments rather than focusing solely on unit price, thereby aligning incentives for long-term supply relationships and quality outcomes that matter most to developers and diagnostic manufacturers.

Transparent mixed-methods research approach combining expert interviews, supplier audits, and technical literature synthesis to derive validated insights and actionable recommendations

This research synthesis is grounded in a mixed-methods approach that combines primary engagement with technical stakeholders, supplier audits, and secondary synthesis of peer-reviewed literature, regulatory guidance, and industry technical bulletins. Primary inputs included in-depth interviews with synthesis chemists, procurement leaders, and quality professionals to capture operational realities and supplier performance perceptions, complemented by site-level discussions that illuminated manufacturing constraints and capacity considerations. Secondary sources were critically appraised to extract validated technical trends, analytical methodologies, and regulatory precedents relevant to oligonucleotide reagent production.

The methodological framework emphasized triangulation to reconcile divergent perspectives and to surface robust insights about supplier differentiation, product performance attributes, and regional manufacturing dynamics. Quality control data, where available, informed discussions on impurity profiling and analytical requirements, while trade and logistics analyses were used to model supply chain stress scenarios. Throughout, care was taken to ensure analytic transparency, document assumption boundaries, and prioritize actionable findings that support decision-making for procurement, R&D, and commercial strategy teams.

Strategic synthesis of trends showing why aligning quality, production scale, and commercial models with evolving therapeutic and diagnostic requirements will determine future leadership

In conclusion, phosphoramidites remain a cornerstone technology for the expanding field of oligonucleotide science, yet the supplier and procurement landscape is undergoing substantive change. Technological advancements in automation and modified chemistries are raising the technical bar for reagent quality and documentation, while trade policy and regional manufacturing developments are prompting strategic adjustments in sourcing and capacity planning. End users across academia, contract research, diagnostics, and biopharma now demand a more integrated value proposition from suppliers that combines technical innovation with supply reliability and regulatory readiness.

Stakeholders who proactively align product development, quality systems, and commercial models with emerging therapeutic and diagnostic needs will be best positioned to capture value and mitigate operational risk. The coming period will reward those who invest in scalable GMP pathways, robust analytical platforms, and diversified production footprints that can respond to both localized demand surges and global supply chain shocks. Organizations that adopt these priorities will enhance their ability to support complex oligonucleotide programs from early discovery through to clinical delivery.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Phosphoramidite Market, by Type

  • 8.1. Modified Phosphoramidite
  • 8.2. Single Base Phosphoramidite
  • 8.3. Specialty Phosphoramidite
  • 8.4. Universal Phosphoramidite

9. Phosphoramidite Market, by Form

  • 9.1. Solid Powder
  • 9.2. Solution

10. Phosphoramidite Market, by Application

  • 10.1. DNA Oligonucleotide Synthesis
  • 10.2. Peptide Nucleic Acid Synthesis
  • 10.3. RNA Oligonucleotide Synthesis

11. Phosphoramidite Market, by End User

  • 11.1. Academic Research Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Diagnostics Companies
  • 11.4. Pharmaceutical Biotechnology Companies

12. Phosphoramidite Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Phosphoramidite Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Phosphoramidite Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Phosphoramidite Market

16. China Phosphoramidite Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AAT Bioquest, Inc.
  • 17.6. Actylis
  • 17.7. Amadis Chemical Company Limited
  • 17.8. American International Chemical, LLC by LeBaronBrown Industries LLC
  • 17.9. Beijing SBS Genetech Co., Ltd.
  • 17.10. Bioneer Corporation
  • 17.11. Biosynth Ltd.
  • 17.12. BOCSCI Inc.
  • 17.13. ChemGenes Corporation
  • 17.14. Creative Biolabs, Inc.
  • 17.15. Hongene Biotech Corporation
  • 17.16. Integrated DNA Technologies, Inc. by Danaher Corporation
  • 17.17. LGC Genomics Limited
  • 17.18. Lumiprobe Corporation
  • 17.19. Maravai LifeSciences Holdings, Inc.,
  • 17.20. MedChemExpress
  • 17.21. Merck KGaA
  • 17.22. PolyOrg, Inc.
  • 17.23. QIAGEN N.V.
  • 17.24. Thermo Fisher Scientific Inc.
  • 17.25. Tokyo Chemical Industry Co., Ltd.
  • 17.26. Twist Bioscience Corporation
  • 17.27. Wuhu Huaren Science and Technology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PHOSPHORAMIDITE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PHOSPHORAMIDITE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PHOSPHORAMIDITE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES PHOSPHORAMIDITE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA PHOSPHORAMIDITE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PHOSPHORAMIDITE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY MODIFIED PHOSPHORAMIDITE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY MODIFIED PHOSPHORAMIDITE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY MODIFIED PHOSPHORAMIDITE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY SINGLE BASE PHOSPHORAMIDITE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY SINGLE BASE PHOSPHORAMIDITE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY SINGLE BASE PHOSPHORAMIDITE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY SPECIALTY PHOSPHORAMIDITE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY SPECIALTY PHOSPHORAMIDITE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY SPECIALTY PHOSPHORAMIDITE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY UNIVERSAL PHOSPHORAMIDITE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY UNIVERSAL PHOSPHORAMIDITE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY UNIVERSAL PHOSPHORAMIDITE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY SOLID POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY SOLID POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY SOLID POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY DNA OLIGONUCLEOTIDE SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY DNA OLIGONUCLEOTIDE SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY DNA OLIGONUCLEOTIDE SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY PEPTIDE NUCLEIC ACID SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY PEPTIDE NUCLEIC ACID SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY PEPTIDE NUCLEIC ACID SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY RNA OLIGONUCLEOTIDE SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY RNA OLIGONUCLEOTIDE SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY RNA OLIGONUCLEOTIDE SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY DIAGNOSTICS COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY DIAGNOSTICS COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY DIAGNOSTICS COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS PHOSPHORAMIDITE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS PHOSPHORAMIDITE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS PHOSPHORAMIDITE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS PHOSPHORAMIDITE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS PHOSPHORAMIDITE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA PHOSPHORAMIDITE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA PHOSPHORAMIDITE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA PHOSPHORAMIDITE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA PHOSPHORAMIDITE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA PHOSPHORAMIDITE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA PHOSPHORAMIDITE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA PHOSPHORAMIDITE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. LATIN AMERICA PHOSPHORAMIDITE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA PHOSPHORAMIDITE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA PHOSPHORAMIDITE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA PHOSPHORAMIDITE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA PHOSPHORAMIDITE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA PHOSPHORAMIDITE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA PHOSPHORAMIDITE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA PHOSPHORAMIDITE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE PHOSPHORAMIDITE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE PHOSPHORAMIDITE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE PHOSPHORAMIDITE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE PHOSPHORAMIDITE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE PHOSPHORAMIDITE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. MIDDLE EAST PHOSPHORAMIDITE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. MIDDLE EAST PHOSPHORAMIDITE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. MIDDLE EAST PHOSPHORAMIDITE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST PHOSPHORAMIDITE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST PHOSPHORAMIDITE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. AFRICA PHOSPHORAMIDITE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. AFRICA PHOSPHORAMIDITE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. AFRICA PHOSPHORAMIDITE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 79. AFRICA PHOSPHORAMIDITE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA PHOSPHORAMIDITE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC PHOSPHORAMIDITE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC PHOSPHORAMIDITE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC PHOSPHORAMIDITE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC PHOSPHORAMIDITE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC PHOSPHORAMIDITE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. ASEAN PHOSPHORAMIDITE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. ASEAN PHOSPHORAMIDITE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. ASEAN PHOSPHORAMIDITE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 90. ASEAN PHOSPHORAMIDITE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. ASEAN PHOSPHORAMIDITE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. GCC PHOSPHORAMIDITE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GCC PHOSPHORAMIDITE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. GCC PHOSPHORAMIDITE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 95. GCC PHOSPHORAMIDITE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. GCC PHOSPHORAMIDITE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPEAN UNION PHOSPHORAMIDITE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPEAN UNION PHOSPHORAMIDITE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPEAN UNION PHOSPHORAMIDITE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPEAN UNION PHOSPHORAMIDITE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPEAN UNION PHOSPHORAMIDITE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. BRICS PHOSPHORAMIDITE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. BRICS PHOSPHORAMIDITE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. BRICS PHOSPHORAMIDITE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 105. BRICS PHOSPHORAMIDITE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. BRICS PHOSPHORAMIDITE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. G7 PHOSPHORAMIDITE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. G7 PHOSPHORAMIDITE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. G7 PHOSPHORAMIDITE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 110. G7 PHOSPHORAMIDITE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. G7 PHOSPHORAMIDITE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. NATO PHOSPHORAMIDITE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. NATO PHOSPHORAMIDITE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. NATO PHOSPHORAMIDITE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 115. NATO PHOSPHORAMIDITE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. NATO PHOSPHORAMIDITE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PHOSPHORAMIDITE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. UNITED STATES PHOSPHORAMIDITE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 119. UNITED STATES PHOSPHORAMIDITE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. UNITED STATES PHOSPHORAMIDITE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 121. UNITED STATES PHOSPHORAMIDITE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. UNITED STATES PHOSPHORAMIDITE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. CHINA PHOSPHORAMIDITE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 124. CHINA PHOSPHORAMIDITE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. CHINA PHOSPHORAMIDITE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 126. CHINA PHOSPHORAMIDITE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. CHINA PHOSPHORAMIDITE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)